Physician profile
Gillian Goree
NPI 1861264772
$541.39
in general payments reported to CMS, 2019-2025
13 companies · $308 in 2025
The $308 reported for 2025 was more than what 75% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.07 · 2024: $219 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.44 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $108.41 | 2025 | Veozah |
| Exeltis, USA INC. | $69.27 | 2024-2025 | Slynd |
| Coopersurgical, INC. | $48.92 | 2024-2025 | Paragard T 380a |
| Abbvie INC. | $48.07 | 2024-2025 | |
| Evofem Biosciences, INC. | $45.65 | 2023-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $37.00 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $35.98 | 2024 | Gardasil 9, Gardasil |
| Mayne Pharma Commercial LLC | $35.25 | 2024 | |
| Millicent US INC | $31.11 | 2024-2025 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $30.79 | 2024-2025 | |
| Si-Bone, INC. | $20.27 | 2025 | |
| Sage Therapeutics, LLC | $15.84 | 2024 | |
| Axonics, INC. | $14.83 | 2024 | Bulkamid, Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Goree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.